阿扎丙宗与萘普生治疗类风湿性关节炎的比较。
Comparison of azapropazone and naproxen in rheumatoid arthritis.
作者信息
Capell H A, McLeod M M, Hernández L A, Grennan D M, Templeton J S
出版信息
Curr Med Res Opin. 1976;4(4):285-9. doi: 10.1185/03007997609109319.
A double-blind crossover trial was carried out in 15 patients with definite rheumatoid arthritis to compare the effectiveness of 1200 mg azapropazone daily and 750 mg naproxen daily, each drug being given for 2 weeks. Patients also received placebo therapy before and between the two treatment periods. The results of subjective and objective assessments showed that both drugs were significantly superior to placebo, but no significant difference could be demonstrated between the two drugs.
对15例确诊的类风湿性关节炎患者进行了一项双盲交叉试验，以比较每日服用1200毫克阿扎丙宗和每日服用750毫克萘普生的疗效，每种药物服用2周。患者在两个治疗期之前和之间还接受了安慰剂治疗。主观和客观评估结果表明，两种药物均显著优于安慰剂，但两种药物之间未显示出显著差异。
Zotero 插件